Research programme: dopamine D3 receptor antagonists - Servier

Drug Profile

Research programme: dopamine D3 receptor antagonists - Servier

Alternative Names: S33084

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Servier
  • Class Antipsychotics; Benzopyrans; Pyrroles
  • Mechanism of Action Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Parkinsonian disorders
  • Discontinued Drug-induced dyskinesia; Psychotic disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinsonian disorders in France
  • 07 Nov 2007 Pharmacodynamics data from a preclinical rat model of Parkinson's disease presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
  • 12 Dec 2005 Preclinical trials in Tardive dyskinesia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top